CSIRO tweet, page-8

Sobering thought, incumbent giant with a TAVR product, shortly, in the market, Admedus product still in early development.

Regardless of how ‘superior’  Admedus TAVR may be (?) once again Admedus is in  a sprint race against the incumbent giants, a sprint where Admedus is way, way  behind the ‘front runners’ in its ability to successfully; 

: Complete R&D
: Some  notable measure of self sufficiency (beyond current revenue)
: Find a partner, and more importantly
: Succesfully commercialise in a timely manner.

History so far has shown that Admedus has always struggled to do all the above in a ‘timely’ manner’, imo.

Anything less than a Admedus TAVR deal that sees at least 3 quarters of cash burn covered, in the  immediate future, will be of little benefit to current retail holders and sp, again imo.

Of note would be market reaction, or lack of, on announcement of; Third party signed up on TAVR deal to cover R&D costs with small upfront (imo, well under 20 mill).

Market does not want to ‘know’ this company at this time, the continual CRs and excessive cash burn have seen to that and perhaps serious doubts to this company being able to deliver the ‘goods’ IN its present form.

WP would indeed be a ‘rain maker’ if he and the BOD could turn this around to the benefit of current retail shareholders, meanwhile there has been plenty of ‘collateral damage’, large portion of the company sold off at a sp that one year ago would have seen ridiculous, and the fact that investors, bar the astute traders, have lost how much?